JP7038664B2 - 操作された腫瘍溶解性ウイルス - Google Patents

操作された腫瘍溶解性ウイルス Download PDF

Info

Publication number
JP7038664B2
JP7038664B2 JP2018555311A JP2018555311A JP7038664B2 JP 7038664 B2 JP7038664 B2 JP 7038664B2 JP 2018555311 A JP2018555311 A JP 2018555311A JP 2018555311 A JP2018555311 A JP 2018555311A JP 7038664 B2 JP7038664 B2 JP 7038664B2
Authority
JP
Japan
Prior art keywords
virus
tumor
ligand
gene
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018555311A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019501671A (ja
JP2019501671A5 (enExample
Inventor
コフィン，ロバート
Original Assignee
レプリミュン リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57796748&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7038664(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1600381.6A external-priority patent/GB201600381D0/en
Priority claimed from GBGB1600382.4A external-priority patent/GB201600382D0/en
Priority claimed from GBGB1600380.8A external-priority patent/GB201600380D0/en
Application filed by レプリミュン リミテッド filed Critical レプリミュン リミテッド
Publication of JP2019501671A publication Critical patent/JP2019501671A/ja
Publication of JP2019501671A5 publication Critical patent/JP2019501671A5/ja
Priority to JP2022034569A priority Critical patent/JP2022078225A/ja
Publication of JP7038664B2 publication Critical patent/JP7038664B2/ja
Application granted granted Critical
Priority to JP2024119344A priority patent/JP2024153748A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16633—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2018555311A 2016-01-08 2017-01-09 操作された腫瘍溶解性ウイルス Active JP7038664B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022034569A JP2022078225A (ja) 2016-01-08 2022-03-07 操作された腫瘍溶解性ウイルス
JP2024119344A JP2024153748A (ja) 2016-01-08 2024-07-25 操作された腫瘍溶解性ウイルス

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB1600382.4 2016-01-08
GBGB1600380.8A GB201600380D0 (en) 2016-01-08 2016-01-08 Modified virus
GBGB1600381.6A GB201600381D0 (en) 2016-01-08 2016-01-08 Virus strain
GB1600381.6 2016-01-08
GBGB1600382.4A GB201600382D0 (en) 2016-01-08 2016-01-08 Engineered virus
GB1600380.8 2016-01-08
PCT/GB2017/050038 WO2017118866A1 (en) 2016-01-08 2017-01-09 Engineered virus

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022034569A Division JP2022078225A (ja) 2016-01-08 2022-03-07 操作された腫瘍溶解性ウイルス

Publications (3)

Publication Number Publication Date
JP2019501671A JP2019501671A (ja) 2019-01-24
JP2019501671A5 JP2019501671A5 (enExample) 2020-01-30
JP7038664B2 true JP7038664B2 (ja) 2022-03-18

Family

ID=57796748

Family Applications (8)

Application Number Title Priority Date Filing Date
JP2018555311A Active JP7038664B2 (ja) 2016-01-08 2017-01-09 操作された腫瘍溶解性ウイルス
JP2018555310A Active JP7038065B2 (ja) 2016-01-08 2017-01-09 腫瘍溶解性ウイルス株
JP2018555309A Active JP6959258B2 (ja) 2016-01-08 2017-01-09 改変された腫瘍溶解性ウイルス
JP2021163811A Active JP7295192B2 (ja) 2016-01-08 2021-10-05 改変された腫瘍溶解性ウイルス
JP2022034569A Pending JP2022078225A (ja) 2016-01-08 2022-03-07 操作された腫瘍溶解性ウイルス
JP2023094818A Pending JP2023113885A (ja) 2016-01-08 2023-06-08 改変された腫瘍溶解性ウイルス
JP2024119344A Pending JP2024153748A (ja) 2016-01-08 2024-07-25 操作された腫瘍溶解性ウイルス
JP2025128636A Pending JP2025163138A (ja) 2016-01-08 2025-07-31 改変された腫瘍溶解性ウイルス

Family Applications After (7)

Application Number Title Priority Date Filing Date
JP2018555310A Active JP7038065B2 (ja) 2016-01-08 2017-01-09 腫瘍溶解性ウイルス株
JP2018555309A Active JP6959258B2 (ja) 2016-01-08 2017-01-09 改変された腫瘍溶解性ウイルス
JP2021163811A Active JP7295192B2 (ja) 2016-01-08 2021-10-05 改変された腫瘍溶解性ウイルス
JP2022034569A Pending JP2022078225A (ja) 2016-01-08 2022-03-07 操作された腫瘍溶解性ウイルス
JP2023094818A Pending JP2023113885A (ja) 2016-01-08 2023-06-08 改変された腫瘍溶解性ウイルス
JP2024119344A Pending JP2024153748A (ja) 2016-01-08 2024-07-25 操作された腫瘍溶解性ウイルス
JP2025128636A Pending JP2025163138A (ja) 2016-01-08 2025-07-31 改変された腫瘍溶解性ウイルス

Country Status (13)

Country Link
US (13) US10570377B2 (enExample)
EP (8) EP3400290B1 (enExample)
JP (8) JP7038664B2 (enExample)
KR (2) KR20250026348A (enExample)
CN (3) CN109153977B (enExample)
AU (2) AU2017205216B2 (enExample)
CA (3) CA3011009A1 (enExample)
DK (4) DK3400291T4 (enExample)
ES (4) ES2831080T5 (enExample)
IL (2) IL260480B (enExample)
MX (1) MX2018008413A (enExample)
SG (2) SG10202108724YA (enExample)
WO (4) WO2017118865A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022002531A (ja) * 2016-01-08 2022-01-11 レプリミュン リミテッド 改変された腫瘍溶解性ウイルス

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60115600T2 (de) * 2000-01-21 2006-07-20 Biovex Ltd. Virusstämme für die onkolytische behandlung von krebs
PT2529747T (pt) 2005-12-02 2018-05-09 Icahn School Med Mount Sinai Vírus da doença de newcastle quiméricos que apresentam proteínas de superfície não nativas e suas utilizações
JP2010529820A (ja) 2007-05-31 2010-08-26 クリシュナン ラム 最小限の固定子鉄心を備えたスイッチドリラクタンス機
NZ711946A (en) 2013-03-14 2020-05-29 Icahn School Med Mount Sinai Newcastle disease viruses and uses thereof
WO2016146143A1 (en) 2015-03-16 2016-09-22 Amal Therapeutics Sa Cell penetrating peptides and complexes comprising the same
BR112018000917A2 (pt) 2015-07-16 2018-09-11 Bioxcel Therapeutics Inc abordagem inovadora para o tratamento de câncer através da imunomodulação
AR107469A1 (es) 2016-01-27 2018-05-02 Oncorus Inc Vectores virales oncolíticos y sus usos
RU2748378C2 (ru) 2016-03-16 2021-05-25 Амаль Терапьютикс Са Комбинация модулятора иммунных контрольных точек и комплекса, содержащего проникающий в клетку пептид, карго-молекулу и пептидный агонист tlr, для применения в медицине
CN108350468B (zh) * 2016-04-22 2020-10-30 深圳市亦诺微医药科技有限公司 用于癌症治疗的溶瘤性单纯疱疹病毒(oHSV)专性载体及其构建体的构建
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
US20190336552A1 (en) 2016-05-30 2019-11-07 Astellas Pharma Inc. Genetically engineered vaccinia viruses
US10888594B2 (en) 2016-05-30 2021-01-12 National University Corporation Tottori University Genetically engineered vaccinia viruses
WO2018006005A1 (en) * 2016-06-30 2018-01-04 Oncorus, Inc. Pseudotyped oncolytic viral delivery of therapeutic polypeptides
DK3515476T3 (da) 2016-09-21 2024-09-02 Amal Therapeutics Sa Fusion der omfatter et cellepenetrerende peptid, en multiepitop og en trl-peptidagnost til behandlingen af cancer
CN108261426B (zh) * 2017-01-04 2019-04-05 杭州康万达医药科技有限公司 药物组合物及其在治疗肿瘤和/或癌症的药物中的应用
GB201700350D0 (en) * 2017-01-09 2017-02-22 Replimune Ltd Altered virus
CN110678750A (zh) 2017-04-28 2020-01-10 美国默沙东药厂 用于癌症治疗的生物标志物
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
CA3070299A1 (en) 2017-07-26 2019-01-31 Oncorus, Inc. Oncolytic viral vectors and uses thereof
JP7079171B2 (ja) 2017-08-03 2022-06-01 アムジエン・インコーポレーテツド インターロイキン－２１ムテイン及び治療方法
MX2020002502A (es) 2017-09-08 2020-07-20 Amgen Inc Inhibidores de kras g12c y metodos para utilizarlos.
CN109554353B (zh) * 2017-09-26 2021-08-06 杭州康万达医药科技有限公司 分离的重组溶瘤痘病毒、药物组合物及其在治疗肿瘤和/或癌症的药物中的用途
EP3708657A4 (en) * 2017-11-08 2021-08-25 Kagoshima University ONCOLYTIC VIRUS (ONCOLYTIC IMMUNOTHERAPY) THAT IS CAPABLE OF TREATING METASTATIC CANCER ALSO WITH ENSURED SAFETY, WITH EXPRESSION CONTROL SYSTEM THAT BUILDS AN OPTIMAL EXPRESSION LEVEL
EP3710035A4 (en) * 2017-11-13 2021-12-29 Bioxcel Therapeutics, Inc. Methods and compositions for treating cancer by modifying multiple arms of the immune system
JP2021508477A (ja) 2017-12-29 2021-03-11 オンコラス， インコーポレイテッド 治療用ポリペプチドの腫瘍溶解性ウイルス送達
US11518808B2 (en) 2018-01-12 2022-12-06 Amgen Inc. Anti-PD-1 antibodies and methods of treatment
WO2019147982A1 (en) * 2018-01-26 2019-08-01 Celldex Therapeutics, Inc. Methods of treating cancer with dendritic cell mobilizing agents
GB201804473D0 (en) * 2018-03-21 2018-05-02 Valo Therapeutics Oy Modified oncolytic adenoviruses
CN108635380A (zh) * 2018-04-13 2018-10-12 北京唯源立康生物科技有限公司 重组溶瘤病毒组合物及其在制备用于治疗肿瘤的药物中的应用
CA3103371A1 (en) * 2018-06-21 2019-12-26 Replimune Limited Treatment using oncolytic virus
WO2020006486A1 (en) * 2018-06-29 2020-01-02 Krystal Biotech, Inc. Compositions and methods for antibody delivery
CN109161561A (zh) * 2018-08-09 2019-01-08 湖北科技学院 一种选择性杀灭前列腺癌细胞的新型溶瘤病毒及其构建方法
EP3837277A4 (en) 2018-08-17 2022-05-11 Icahn School of Medicine at Mount Sinai RECOMBINANT NEWCASTLE DISEASE VIRUSES AND THEIR USES IN THE PREVENTION OF RSV DISEASE OR HUMAN METAPNEUMOVIRUS INFECTION
WO2020052551A1 (en) * 2018-09-10 2020-03-19 Genesail Biotech (Shanghai) Co. Ltd. A modified oncolytic virus, composition and use thereof
KR20210065976A (ko) * 2018-09-26 2021-06-04 아스텔라스세이야쿠 가부시키가이샤 종양 용해성 백시니아 바이러스와 면역 체크포인트 저해제의 병용에 의한 암 요법 그리고 이것에 사용하기 위한 의약 조성물 및 조합 의약
JP7566750B2 (ja) 2018-12-27 2024-10-15 アムジェン インコーポレイテッド 凍結乾燥ウイルス製剤
CN111606999B (zh) * 2019-02-26 2022-09-06 南京惟亚德生物医药有限公司 兼具激活免疫共刺激信号通路和阻断免疫检查点的复制型溶瘤腺病毒及其应用
EP3935182A1 (en) * 2019-03-05 2022-01-12 Amgen Inc. Use of oncolytic viruses for the treatment of cancer
TW202102543A (zh) 2019-03-29 2021-01-16 美商安進公司 溶瘤病毒在癌症新輔助療法中之用途
CN110054678B (zh) * 2019-05-16 2023-04-18 中国医学科学院血液病医院（血液学研究所） 一种膜结合型mFLT3LG蛋白及其应用
CN110218707B (zh) * 2019-05-29 2021-10-22 上海市公共卫生临床中心 一种新型溶瘤病毒及其制备方法和应用
KR20220044310A (ko) * 2019-08-05 2022-04-07 고쿠리츠 다이가쿠 호우징 도우카이 고쿠리츠 다이가쿠 기코우 악성 종양을 치료하기 위한 병용약, 악성 종양을 치료하기 위한 의약 조성물 및 악성 종양 치료용 의약 조성물
CA3156880A1 (en) * 2019-11-06 2021-05-14 Memgen, Inc. Replication-enhanced oncolytic adenoviruses
CN110982794B (zh) * 2020-03-05 2020-06-16 北京唯源立康生物科技有限公司 一种修饰的单纯疱疹病毒
CN110982795B (zh) * 2020-03-05 2020-06-16 北京唯源立康生物科技有限公司 一种单纯疱疹病毒及其用途
WO2021175293A1 (zh) * 2020-03-05 2021-09-10 北京唯源立康生物科技有限公司 一种单纯疱疹病毒及其用途
WO2021193081A1 (ja) * 2020-03-23 2021-09-30 国立大学法人東海国立大学機構 １型単純ヘルペスウイルス
CN116096906A (zh) 2020-06-29 2023-05-09 旗舰创业创新五公司 工程化以促进萨诺传递的病毒及其在治疗癌症中的用途
US11839659B2 (en) 2020-07-02 2023-12-12 Northwestern University Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of indoleamine 2,3-dioxygenase (IDO) protein
CN112941039A (zh) * 2021-02-01 2021-06-11 南京大学 一种新型类囊泡溶瘤病毒及其在制备抗肿瘤药物上的应用
DE102022104146A1 (de) 2021-03-19 2022-09-22 Yamada Manufacturing Co., Ltd. Lenkvorrichtung
US20240191252A1 (en) * 2021-04-08 2024-06-13 Immvira Biopharmaceuticals Co., Limited Genetically modified oncolytic herpes simplex virus delivering chemokine and tumor associated/specific antigen
US20240245739A1 (en) * 2021-05-18 2024-07-25 The Penn State Research Foundation Oncolytic virus based cancer therapy
CN113583979B (zh) * 2021-08-03 2022-11-22 杭州荣谷生物科技有限公司 一种重组溶瘤痘苗病毒、制备方法及其用途
WO2023136212A1 (ja) 2022-01-11 2023-07-20 三菱マテリアル株式会社 表面被覆切削工具
WO2024055022A2 (en) * 2022-09-08 2024-03-14 Virogin Biotech Canada Ltd Oncolytic virus expressing an immune cell engager for tumor targeting
WO2025248110A1 (en) * 2024-05-31 2025-12-04 Replimune Limited An oncolytic herpes simplex virus (hsv) and an anti-pd-1 antibody for use in treating braf mutant melanoma

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006528484A (ja) 2003-07-25 2006-12-21 バイオヴェックス リミテッド ウイルスベクター
JP2015526525A (ja) 2012-08-30 2015-09-10 アムジエン・インコーポレーテツド 単純ヘルペスウイルスおよび免疫チェックポイント阻害薬を使用して、メラノーマを治療するための方法
JP2019500909A (ja) 2016-01-08 2019-01-17 レプリミュン リミテッド 腫瘍溶解性ウイルス株

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU594014B2 (en) 1984-03-21 1990-03-01 Research Corporation Technologies, Inc. Recombinant DNA molecules
US5288641A (en) 1984-06-04 1994-02-22 Arch Development Corporation Herpes Simplex virus as a vector
CA1282721C (en) 1984-06-04 1991-04-09 Bernard Roizman Herpes simplex virus as a vector
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5698531A (en) 1989-03-31 1997-12-16 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5328688A (en) 1990-09-10 1994-07-12 Arch Development Corporation Recombinant herpes simplex viruses vaccines and methods
US6770274B1 (en) 1990-09-14 2004-08-03 The General Hospital Corporation Viral mutant HSV mediated destruction of neoplastic cells
US6040169A (en) 1991-01-31 2000-03-21 Medical Research Council Herpes simplex virus-1 deletion variants and vaccines thereof
DE69332525T2 (de) 1992-03-31 2003-04-17 Arch Development Corp., Chicago Behandlung von Tumorerkrankungen mit modifiziertem HSV
US6699468B1 (en) 1994-06-23 2004-03-02 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
CA2234060A1 (en) 1995-10-06 1997-04-10 Arch Development Corporation Methods and compositions for viral enhancement of cell killing
US5824318A (en) 1996-07-24 1998-10-20 American Cyanamid Company Avirulent herpetic viruses useful as tumoricidal agents and vaccines
GB9700411D0 (en) 1997-01-10 1997-02-26 Univ London Eukaryotic gene expression cassette and uses thereof
US6379674B1 (en) 1997-08-12 2002-04-30 Georgetown University Use of herpes vectors for tumor therapy
US7300774B1 (en) 1999-12-09 2007-11-27 The Regents Of The University Of California Multimeric fusion proteins of the TNF superfamily ligands
US6428968B1 (en) 1999-03-15 2002-08-06 The Trustees Of The University Of Pennsylvania Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
CA2388807C (en) 1999-11-12 2013-08-06 Matthew C. Coffey Viruses for the treatment of cellular proliferative disorders
DE60115600T2 (de) 2000-01-21 2006-07-20 Biovex Ltd. Virusstämme für die onkolytische behandlung von krebs
ATE508635T1 (de) 2001-03-27 2011-05-15 Catherex Inc Virusvektoren und ihre verwendung bei therapeutischen methoden
US7731952B2 (en) 2004-06-24 2010-06-08 New York University Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
MX2007003804A (es) 2004-11-04 2007-04-23 Pfizer Prod Inc Tratamiento combinado de anticuerpo anti-ctla4 e inhibidor de aromatasa para el cancer de mama.
US9866961B2 (en) 2004-12-01 2018-01-09 Todd Beauchamp Multi-channel loudspeaker enclosure with laterally projecting wings and method for orienting and driving multiple loudspeakers
LT2620450T (lt) 2005-03-08 2019-02-11 Pfizer Products Inc. Anti-ctla-4 antikūnų kompozicijos
HUE029789T2 (en) 2005-05-06 2017-04-28 Providence Health & Services - Oregon Trimer OX40 Immunoglobulin Fusion Protein and Methods of Application
US8986672B2 (en) 2005-06-23 2015-03-24 The University Of Houston Use of mutant Herpes Simplex Virus-2 for cancer therapy
GB0522476D0 (en) 2005-11-03 2005-12-14 Biovex Ltd Oncolytic herpes virus vectors
JP6092497B2 (ja) 2006-03-30 2017-03-08 ユニバーシティー オブ カリフォルニア 抗ｃｔｌａ−４抗体の限局性分泌のための方法および組成物
US8313896B2 (en) * 2008-04-04 2012-11-20 The General Hospital Corporation Oncolytic herpes simplex virus immunotherapy in the treatment of brain cancer
WO2009148488A2 (en) 2008-05-29 2009-12-10 The General Hospital Corporation Use of oncolytic herpes viruses for killing cancer stem cells
CN102575227A (zh) 2008-10-08 2012-07-11 英特瑞克斯顿股份有限公司 表达多种免疫调节剂的工程改造细胞及其应用
US20100297072A1 (en) 2009-05-19 2010-11-25 Depinho Ronald A Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer Therapy
JP2013511549A (ja) 2009-11-20 2013-04-04 インフィニティー ファーマシューティカルズ， インコーポレイテッド ヘッジホッグ関連癌の治療のための方法及び組成物
WO2011119925A2 (en) * 2010-03-25 2011-09-29 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthetic herpes simplex viruses for treatment of cancers
WO2011118866A1 (ko) 2010-03-26 2011-09-29 연세대학교 산학협력단 네트워크를 통한 심사요청 방법
BR112013006699A2 (pt) * 2010-09-24 2016-06-14 Oncos Therapeutics Oy vetor adenoviral oncolítico que codifica anticorpos anti-ctl4-4 monoclonais, célula e composição farmacêutica compreendendo o mesmo, método de produção de anticorpo monoclonal humano específico para ctla-4 em uma célula e uso do referido vetor adenoviral
PT2753355T (pt) * 2011-09-08 2019-02-01 Univ New York Vírus herpes simplex oncolítico e suas utilizações terapêuticas
FI20115914L (fi) 2011-09-16 2013-03-17 Oncos Therapeutics Ltd Muunnettu onkolyyttinen virus
EP2806883B1 (en) * 2012-01-25 2019-04-24 DNAtrix, Inc. Biomarkers and combination therapies using oncolytic virus and immunomodulation
EP2879498A4 (en) 2012-07-30 2016-03-30 Alex Wah Hin Yeung BY TREATMENT OF AT LEAST TWO OR ALL THREE OF THE FOLLOWING COMPONENTS SUCH AS TUMOR CELLS, AN ONCOLYTIC VIRUS VECTOR WITH TRANSGENIC EXPRESSION OF GM-CSF AND AN IMMUNE TEST MODULE DEVELOPED TUMOR SPECIFIC LIVING AND IN VIVO CANCER VACCINE SYSTEM
US9789182B2 (en) 2012-10-23 2017-10-17 Bristol-Myers Squibb Company Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancer
EP2958592A1 (en) 2013-02-22 2015-12-30 F. Hoffmann-La Roche AG Methods of treating cancer and preventing drug resistance
NZ711946A (en) 2013-03-14 2020-05-29 Icahn School Med Mount Sinai Newcastle disease viruses and uses thereof
PT3508209T (pt) 2013-09-03 2022-05-27 Medimmune Ltd Composições que apresentam um vírus da doença de newcastle atenuado e métodos de utilização para o tratamento de neoplasias
TR201802728T4 (tr) 2013-10-25 2018-03-21 Psioxus Therapeutics Ltd Heterolog genlerle donatılmış onkolitik adenovirüsler.
CN106068326B (zh) 2013-10-28 2021-06-18 联邦高等教育系统-匹兹堡大学 溶瘤性hsv载体
WO2015077624A1 (en) 2013-11-22 2015-05-28 Dnatrix, Inc. Adenovirus expressing immune cell stimulatory receptor agonist(s)
WO2015128313A1 (en) 2014-02-25 2015-09-03 Deutsches Krebsforschungszentrum Rna viruses for immunovirotherapy
MA39818A (fr) * 2014-03-30 2017-02-08 Benevir Biopharm Inc Virus oncolytiques « armés » comprenant un inhibiteur de tap exogène et leurs utilisations thérapeutiques
KR102504758B1 (ko) 2014-07-16 2023-02-28 트랜스진 종양 세포 붕괴성 바이러스와 면역 체크포인트 조절제의 배합물
CA3190510A1 (en) 2014-07-16 2016-01-21 Transgene Sa Oncolytic virus for expression of immune checkpoint modulators
US20160040186A1 (en) 2014-08-07 2016-02-11 Xiaoyun Liu Dna construct and method for transgene expression
GB201419579D0 (en) 2014-11-03 2014-12-17 Iomet Pharma Ltd Pharmaceutical compound
US10525557B2 (en) 2015-01-23 2020-01-07 Dreamwell, Ltd. Automated mattress manufacturing process and apparatus
CN108350468B (zh) 2016-04-22 2020-10-30 深圳市亦诺微医药科技有限公司 用于癌症治疗的溶瘤性单纯疱疹病毒(oHSV)专性载体及其构建体的构建
GB201700350D0 (en) * 2017-01-09 2017-02-22 Replimune Ltd Altered virus
US12029647B2 (en) * 2017-03-07 2024-07-09 4C Medical Technologies, Inc. Systems, methods and devices for prosthetic heart valve with single valve leaflet
CA3103371A1 (en) 2018-06-21 2019-12-26 Replimune Limited Treatment using oncolytic virus
SG11202106460XA (en) 2018-12-21 2021-07-29 Ottawa Hospital Res Inst Modified orthopoxvirus vectors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006528484A (ja) 2003-07-25 2006-12-21 バイオヴェックス リミテッド ウイルスベクター
JP2015526525A (ja) 2012-08-30 2015-09-10 アムジエン・インコーポレーテツド 単純ヘルペスウイルスおよび免疫チェックポイント阻害薬を使用して、メラノーマを治療するための方法
JP2019500909A (ja) 2016-01-08 2019-01-17 レプリミュン リミテッド 腫瘍溶解性ウイルス株

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Cancer Gene Therapy，2014年，Vol.21，p.340-348
Cancer Research，2006年，Vol.66, No.9，p.4835-4842
Gene Therapy，2003年，Vol.10, No.4，p.292-303

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022002531A (ja) * 2016-01-08 2022-01-11 レプリミュン リミテッド 改変された腫瘍溶解性ウイルス
JP7295192B2 (ja) 2016-01-08 2023-06-20 レプリミュン リミテッド 改変された腫瘍溶解性ウイルス
JP2023113885A (ja) * 2016-01-08 2023-08-16 レプリミュン リミテッド 改変された腫瘍溶解性ウイルス

Also Published As

Publication number Publication date
EP4219696A2 (en) 2023-08-02
US20190032024A1 (en) 2019-01-31
US12458696B2 (en) 2025-11-04
EP3400293B1 (en) 2020-09-16
HK1257480A1 (en) 2019-10-18
US20200208122A1 (en) 2020-07-02
CA3010987A1 (en) 2017-07-13
JP2024153748A (ja) 2024-10-29
EP3400292A1 (en) 2018-11-14
IL282985A (en) 2021-06-30
ES2831080T5 (es) 2023-10-30
HK1257224A1 (en) 2019-10-18
WO2017118866A1 (en) 2017-07-13
EP3400291B2 (en) 2024-02-28
JP2022078225A (ja) 2022-05-24
CN109312309A (zh) 2019-02-05
US20230203453A1 (en) 2023-06-29
AU2022279486B2 (en) 2025-07-31
EP3400291A1 (en) 2018-11-14
MX2018008413A (es) 2019-02-20
DK3400291T4 (da) 2024-04-02
DK3400291T3 (da) 2020-11-30
DK3400290T5 (da) 2024-09-23
US10626377B2 (en) 2020-04-21
US20200199542A1 (en) 2020-06-25
SG11201805835WA (en) 2018-08-30
BR112018013930A2 (pt) 2018-12-11
US20210254019A1 (en) 2021-08-19
US10612005B2 (en) 2020-04-07
US20240301365A1 (en) 2024-09-12
CN109312309B (zh) 2024-04-02
DK3400290T3 (da) 2023-05-01
ES2841300T5 (es) 2024-08-06
JP2019500909A (ja) 2019-01-17
EP3400290A1 (en) 2018-11-14
CN109415703A (zh) 2019-03-01
ES2943150T3 (es) 2023-06-09
US12465639B2 (en) 2025-11-11
EP3805376A1 (en) 2021-04-14
ES3041885T3 (en) 2025-11-17
EP3400293B2 (en) 2023-07-12
EP4219696A3 (en) 2023-09-27
DK3400293T4 (da) 2023-08-28
US11473063B2 (en) 2022-10-18
KR102762431B1 (ko) 2025-02-03
JP7295192B2 (ja) 2023-06-20
KR20250026348A (ko) 2025-02-25
CN109415703B (zh) 2024-08-30
EP4628577A2 (en) 2025-10-08
EP3400292B1 (en) 2020-08-26
US20190040366A1 (en) 2019-02-07
JP2019501671A (ja) 2019-01-24
EP3400290B1 (en) 2023-04-05
ES2831080T3 (es) 2021-06-07
JP2025163138A (ja) 2025-10-28
US12397053B2 (en) 2025-08-26
IL260480B (en) 2021-05-31
CA3011009A1 (en) 2017-07-13
JP2022002531A (ja) 2022-01-11
WO2017118865A1 (en) 2017-07-13
CA3011004A1 (en) 2017-07-13
SG10202108724YA (en) 2021-09-29
AU2022279486A1 (en) 2023-02-02
JP7038065B2 (ja) 2022-03-17
US20230130992A1 (en) 2023-04-27
US10947513B2 (en) 2021-03-16
US20190022157A1 (en) 2019-01-24
US11427810B2 (en) 2022-08-30
CN109153977A (zh) 2019-01-04
WO2017118867A1 (en) 2017-07-13
HK1257074A1 (en) 2019-10-11
EP3400291B1 (en) 2020-11-04
IL282985B (en) 2022-04-01
US20190015466A1 (en) 2019-01-17
DK3400293T3 (da) 2020-10-19
US20240018488A1 (en) 2024-01-18
AU2017205216B2 (en) 2022-11-24
JP6959258B2 (ja) 2021-11-02
EP3805376B1 (en) 2025-08-06
DK3805376T3 (da) 2025-09-29
AU2017205216A1 (en) 2018-08-09
US10570377B2 (en) 2020-02-25
JP2019501670A (ja) 2019-01-24
EP3400293A1 (en) 2018-11-14
US12049647B2 (en) 2024-07-30
CN109153977B (zh) 2022-11-01
KR20180103956A (ko) 2018-09-19
US12024724B2 (en) 2024-07-02
JP2023113885A (ja) 2023-08-16
ES2841300T3 (es) 2021-07-08
EP3778881A1 (en) 2021-02-17
US20250352646A1 (en) 2025-11-20
WO2017118864A1 (en) 2017-07-13
US20230212531A1 (en) 2023-07-06

Similar Documents

Publication Publication Date Title
US12397053B2 (en) Engineered virus
US20210252135A1 (en) Treatment using oncolytic virus
JP2020503871A (ja) 改変ウイルス
HK40049907A (en) Engineered virus
HK40045432A (en) Modified oncolytic virus
HK1257480B (en) Engineered virus

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20190606

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190606

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191212

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191212

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20201127

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210316

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210824

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211117

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220208

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220308

R150 Certificate of patent or registration of utility model

Ref document number: 7038664

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250